TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
The deal includes upfront payments, milestone payments and ongoing royalties
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Subscribe To Our Newsletter & Stay Updated
